News jeff 2018-05-31T11:46:02+00:00

News

TaiRx ranked first in Taiwan for the most innovative pharmaceutical companies in the APAC region

2019/8/30 World-renowned professional [...]

August 30th, 2019|News|

TaiRx receives “Technology and Product or Technology Development is Successful and Marketable” recommendation from Industrial Development Bureau and starts CVM-1118 (Foslinanib) Phase II clinical trial in Taiwan and US.

2019/1/2 TaiRx, Inc. [...]

January 2nd, 2019|News|

TaiRx, Inc. and BioHealth Innovation, Inc. Form TaiRx US to Develop and Commercialize Therapeutics and Precision Medicine Diagnostics- Joint venture to focus on the Nodal protein, a previously untargeted and critical mediator of aggressive cancer progression and treatment resistance

2018/10/23 TaiRx, Inc [...]

October 23rd, 2018|News|

A major milestone for cancer drug development in Taiwan! CVM-1118 approved by the US FDA to start Phase II clinical study in the US.

2018/4/15 TaiRx’s CVM-1118 [...]

April 15th, 2018|News|

A first in Taiwan! In collaboration with Taiwanese API and drug product manufacturers, TaiRx produced the first domestically manufactured selenium trace element drug in Taiwan and was approved by the Taiwan FDA.

2018/3/8 TaiRx, Inc. [...]

March 8th, 2018|News|